Method for expressing polypeptide having anti-tumor activity
US5151349A · kind A · utility
6Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 31, 1990 |
| Grant date | Sep 29, 1992 |
| Priority date | — |
| Expiry date | Jan 31, 2010 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/70
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Disclosed is a human TNF derivative with a reduced tendency to cause adverse side effects that is obtained by replacing the 31st and 32nd arginine residues from the N-terminal of the amino acid sequence of human TNF, which has a potential for causing serious adverse effects, with asparagine residue and threoine residue, respectively, as well as a method of preparing the same utilizing recombinant DNA technology.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.